Published in World J Gastroenterol on February 07, 2014
Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma. World J Gastroenterol (2015) 0.90
TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression. Chin J Cancer Res (2014) 0.90
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol (2015) 0.87
Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment. Biomed Res Int (2015) 0.82
Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncol Lett (2016) 0.81
Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors. Mol Med Rep (2014) 0.80
Retracted miR-128 modulates hepatocellular carcinoma by inhibition of ITGA2 and ITGA5 expression. Am J Transl Res (2015) 0.80
Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol (2015) 0.79
Investigating the mechanism of hepatocellular carcinoma progression by constructing genetic and epigenetic networks using NGS data identification and big database mining method. Oncotarget (2016) 0.78
Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma. World J Gastroenterol (2015) 0.75
BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma. Oncol Lett (2016) 0.75
Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach. PLoS One (2015) 0.75
Can TIE-2 expressing monocytes represent a novel marker for hepatocellular carcinoma? Hepatobiliary Surg Nutr (2014) 0.75
The role of APE/Ref-1 signaling pathway in hepatocellular carcinoma progression. Int J Oncol (2014) 0.75
Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. World J Gastroenterol (2015) 0.75
An ANCCA/PRO2000-miR-520a-E2F2 regulatory loop as a driving force for the development of hepatocellular carcinoma. Oncogenesis (2016) 0.75
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Wnt signaling and cancer. Genes Dev (2000) 18.53
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer (2007) 8.05
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 7.90
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07
Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer (2000) 5.24
Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med (2011) 4.91
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol (2012) 4.21
Tumors as organs: complex tissues that interface with the entire organism. Dev Cell (2010) 3.98
Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda) (2004) 3.79
The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol (2012) 3.42
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A (2010) 3.03
Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res (2004) 2.86
The role of microRNAs in cancer: no small matter. Eur J Cancer (2007) 2.85
Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene (2012) 2.82
S100A4 and metastasis: a small actor playing many roles. Am J Pathol (2009) 2.80
Glypicans. Genome Biol (2008) 2.76
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74
Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev (2012) 2.33
TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene (2009) 2.33
The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta (2006) 2.24
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res (2009) 2.23
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol (2009) 2.19
Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology (1998) 2.14
TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology (2013) 1.94
Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer (2008) 1.88
Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One (2012) 1.82
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol (2011) 1.72
Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology (2001) 1.68
Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology (2005) 1.68
Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res (1997) 1.67
Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res (2009) 1.65
The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal (2012) 1.64
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci (2009) 1.64
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg (2004) 1.62
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene (2007) 1.57
Association between polymorphisms of trinucleotide repeat containing 9 gene and breast cancer risk: evidence from 62,005 subjects. Breast Cancer Res Treat (2010) 1.57
Developing therapeutic microRNAs for cancer. Gene Ther (2011) 1.49
Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem (2011) 1.48
Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene (2013) 1.48
Angiogenesis in pre-malignant conditions. Eur J Cancer (2009) 1.45
Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res (2008) 1.45
Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene (2009) 1.43
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology (2013) 1.41
Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC Cancer (2013) 1.40
Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology (2013) 1.39
The tumor microenvironment in the post-PAGET era. Cancer Lett (2006) 1.39
The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem (2008) 1.36
Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem (2005) 1.36
An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis (2009) 1.36
Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Ageing Dev (2005) 1.34
Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer (2006) 1.30
Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol (2009) 1.29
Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology (2013) 1.27
GRK6 deficiency is associated with enhanced CXCR4-mediated neutrophil chemotaxis in vitro and impaired responsiveness to G-CSF in vivo. J Leukoc Biol (2004) 1.27
First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2013) 1.27
The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells. BMC Cancer (2008) 1.26
Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology (2010) 1.26
Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One (2013) 1.26
miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal (2012) 1.23
Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today (2011) 1.23
Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res (2008) 1.21
Forkhead box transcription factor FoxC1 preserves corneal transparency by regulating vascular growth. Proc Natl Acad Sci U S A (2011) 1.20
Excess body weight and obesity--the link with gastrointestinal and hepatobiliary cancer. Nat Rev Gastroenterol Hepatol (2011) 1.18
MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal (2013) 1.16
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One (2012) 1.15
High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep (2004) 1.13
Changes in the expression of methionine adenosyltransferase genes and S-adenosylmethionine homeostasis during hepatic stellate cell activation. Hepatology (2010) 1.13
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol (2000) 1.13
uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets (2011) 1.12
Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine (2012) 1.12
FOXC1 contributes to microvascular invasion in primary hepatocellular carcinoma via regulating epithelial-mesenchymal transition. Int J Biol Sci (2012) 1.07
Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis. PLoS One (2013) 1.06
The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Cancer Res (2009) 1.05
An insertion/deletion polymorphism in the 3' untranslated region of beta-transducin repeat-containing protein (betaTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese. Biochem Biophys Res Commun (2009) 1.05
Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer (2009) 1.03
Dickkopf1: a tumor suppressor or metastasis promoter? Int J Cancer (2011) 1.03
MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun (2010) 1.02
hGPR87 contributes to viability of human tumor cells. Int J Cancer (2008) 1.01
Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem (2011) 1.01